A late-stage study for fasinumab conducted by Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. hit the mark in assessing patients with chronic pain from osteoarthritis of the knee or hip.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
The earlier a child is diagnosed with type 1 diabetes, the greater the risk of heart disease and a life shortened by as much as 18 years, a large study suggests.
The Janssen Pharmaceutical Companies of Johnson & Johnson confirmed top-line data from the Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of the first investigational long-acting injectable two-drug regimen for the treatment of HIV-1.
A long-acting injection developed by GlaxoSmithKline and given once a month proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.
Adults who sleep too little or too much may have an increased risk of heart attack or stroke, say researchers who argue that the best way to think of the harmful effect is in terms of “excess heart age.”
Among the industry group PhRMA’s findings was that overall R&D spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and from $29.8 billion in 2001.
Shares of Realm Therapeutics plunged more than 50 percent after the company’s Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the study.
A new study suggests that how parents talk to children may matter just as much as how much time they spend talking.
Gemphire Plunges After Investigational Drug Worsens Liver Fat Levels in Pediatric NAFLD Trial Patients
Shares of Gemphire Therapeutics crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease treatment for pediatric patients actually worsened the disease in some patients.
Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.
Pregnant women who have both severe obesity and diabetes may be more likely to have children with autism, ADHD and other psychiatric disorders than mothers who do not have either condition during pregnancy, a new study suggests.
Low-calorie sweetened beverages such as diet sodas that use aspartame or stevia may be a good replacement for full-sugar sodas and fruit juices, but researchers are still unsure about their long-term health effects, according to a new American Heart Association Science Advisory.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Bellerophon Therapeutics’ Phase III pulmonary arterial hypertension drug INOpulse failed to meet endpoints following a pre-specified interim analysis from a Data Monitoring Committee.
An investigational gene therapy treatment for hemophilia A saw a 97 percent response rate after one treatment.
Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significantly
Ovid Therapeutics reported that the Phase II STARS trial of OV101 for Angelman Syndrome showed “robust and statistically significant improvement,” but the company’s stock plunged nearly 30 percent in premarket trading.
Scientists with Framingham, Mass.-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid (Aβ), the primary driver of Alzheimer’s disease.
Colon cancer patients who drink one or more servings of artificially sweetened beverages a day have roughly half the risk of their cancer recurring compared to those who drink few or none of these beverages, a U.S. study suggests.
As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.
Denali Therapeutics stock climbed 11 percent after the release of positive data from the company’s Phase I clinical trial of DNL201 in Parkinson’s disease.